Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer
The objective of this study was to evaluate the acute and medium-term toxicities, the quality of life, and aesthetic results of patients with breast cancer (BC) treated with tomotherapy. This was a prospective study, including patients with BC treated by tomotherapy. Radiation therapy delivered 50 G...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/12/3852 |
id |
doaj-95872fec96314af8a9c851e2865565a3 |
---|---|
record_format |
Article |
spelling |
doaj-95872fec96314af8a9c851e2865565a32020-12-21T00:01:18ZengMDPI AGCancers2072-66942020-12-01123852385210.3390/cancers12123852Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast CancerBenoît Bataille0Bennadji Raoudha1Florence Le Tinier2Laurent Basson3Alexandre Escande4Hélène Langin5Emmanuelle Tresch6Frederik Crop7Franck Darloy8Damien Carlier9Eric Lartigau10David Pasquier11Academic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceAcademic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceAcademic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceAcademic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceAcademic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceAcademic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceMethodology and Biostatistics Department, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceMedical Physics Department, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceDepartment of Radiation Oncology, Leonard De Vinci center, 59187 Dechy, FranceDepartment of Radiation Oncology, Leonard De Vinci center, 59187 Dechy, FranceAcademic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceAcademic Department of Radiation Oncology, Oscar Lambret Comprehensive Cancer Center, 59020 Lille, FranceThe objective of this study was to evaluate the acute and medium-term toxicities, the quality of life, and aesthetic results of patients with breast cancer (BC) treated with tomotherapy. This was a prospective study, including patients with BC treated by tomotherapy. Radiation therapy delivered 50 Gy in 25 fractions to the breast or chest wall and to lymph node areas, with a simultaneous integrated boost at a dose of 60 Gy at the tumor bed in cases of breast conservative surgery. We included 288 patients, 168 and 120 treated with breast-conserving surgery and mastectomy respectively. Two hundred sixty patients (90.3%) received lymph node irradiation. Median follow-up was 25 months (6–48). Acute dermatitis was observed in 278 patients (96.5%), mostly grade 1 (59.7%). The aesthetic aspect of the breast at one year was reported as “good” or “excellent” in 84.6% of patients. The patients’ quality of life improved over time, especially those treated with chemotherapy. The two-year overall survival and disease-free survival were 97.8% (95% confidence interval (CI): 94.1–99.2%), and 93.4% (95% CI: 89.2–96.0%) respectively. Tomotherapy for locally advanced BC has acceptable toxicity, supporting its use in this indication; however, longer follow-up is needed to assess long-term outcomes.https://www.mdpi.com/2072-6694/12/12/3852breast cancerIMRTtomotherapysimultaneous integrated boostquality of life |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Benoît Bataille Bennadji Raoudha Florence Le Tinier Laurent Basson Alexandre Escande Hélène Langin Emmanuelle Tresch Frederik Crop Franck Darloy Damien Carlier Eric Lartigau David Pasquier |
spellingShingle |
Benoît Bataille Bennadji Raoudha Florence Le Tinier Laurent Basson Alexandre Escande Hélène Langin Emmanuelle Tresch Frederik Crop Franck Darloy Damien Carlier Eric Lartigau David Pasquier Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Cancers breast cancer IMRT tomotherapy simultaneous integrated boost quality of life |
author_facet |
Benoît Bataille Bennadji Raoudha Florence Le Tinier Laurent Basson Alexandre Escande Hélène Langin Emmanuelle Tresch Frederik Crop Franck Darloy Damien Carlier Eric Lartigau David Pasquier |
author_sort |
Benoît Bataille |
title |
Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer |
title_short |
Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer |
title_full |
Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer |
title_fullStr |
Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer |
title_full_unstemmed |
Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer |
title_sort |
prospective study of intensity-modulated radiation therapy for locally advanced breast cancer |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-12-01 |
description |
The objective of this study was to evaluate the acute and medium-term toxicities, the quality of life, and aesthetic results of patients with breast cancer (BC) treated with tomotherapy. This was a prospective study, including patients with BC treated by tomotherapy. Radiation therapy delivered 50 Gy in 25 fractions to the breast or chest wall and to lymph node areas, with a simultaneous integrated boost at a dose of 60 Gy at the tumor bed in cases of breast conservative surgery. We included 288 patients, 168 and 120 treated with breast-conserving surgery and mastectomy respectively. Two hundred sixty patients (90.3%) received lymph node irradiation. Median follow-up was 25 months (6–48). Acute dermatitis was observed in 278 patients (96.5%), mostly grade 1 (59.7%). The aesthetic aspect of the breast at one year was reported as “good” or “excellent” in 84.6% of patients. The patients’ quality of life improved over time, especially those treated with chemotherapy. The two-year overall survival and disease-free survival were 97.8% (95% confidence interval (CI): 94.1–99.2%), and 93.4% (95% CI: 89.2–96.0%) respectively. Tomotherapy for locally advanced BC has acceptable toxicity, supporting its use in this indication; however, longer follow-up is needed to assess long-term outcomes. |
topic |
breast cancer IMRT tomotherapy simultaneous integrated boost quality of life |
url |
https://www.mdpi.com/2072-6694/12/12/3852 |
work_keys_str_mv |
AT benoitbataille prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT bennadjiraoudha prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT florenceletinier prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT laurentbasson prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT alexandreescande prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT helenelangin prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT emmanuelletresch prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT frederikcrop prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT franckdarloy prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT damiencarlier prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT ericlartigau prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer AT davidpasquier prospectivestudyofintensitymodulatedradiationtherapyforlocallyadvancedbreastcancer |
_version_ |
1724376026242351104 |